SAR439483 / Sanofi - LARVOL DELTA

Safety and Efficacy of SAR439483 in Patients with Leber Congenital Amaurosis Caused by Biallelic Mutations in GUCY2D (LCA1) (AAO 2022) - No abstract available

Clinical • Late-breaking abstract • Inherited Retinal Dystrophy • Ophthalmology

Study of Subretinally Injected SAR439483 Administered in Patients With Leber Congenital Amaurosis Caused by Biallelic Mutations in GUCY2D (clinicaltrials.gov) - P1/2 | N=15 | Active, not recruiting | Sponsor: Atsena Therapeutics Inc. | Trial completion date: Feb 2022 ➔ May 2027 | Trial primary completion date: Feb 2022 ➔ May 2023 | Recruiting ➔ Active, not recruiting

Enrollment closed • Trial completion date • Trial primary completion date • Inherited Retinal Dystrophy

Study of Subretinally Injected SAR439483 Administered in Patients With Leber Congenital Amaurosis Caused by Biallelic Mutations in GUCY2D (clinicaltrials.gov) - P1/2; N=15; Recruiting; Sponsor: Atsena Therapeutics Inc.; Trial primary completion date: Feb 2021 ➔ Feb 2022

Clinical • Trial primary completion date • Inherited Retinal Dystrophy • Retinal Disorders

Study of Subretinally Injected SAR439483 Administered in Patients With Leber Congenital Amaurosis Caused by Biallelic Mutations in GUCY2D (clinicaltrials.gov) - P1/2; N=15; Recruiting; Sponsor: Atsena Therapeutics Inc.; Active, not recruiting ➔ Recruiting

Clinical • Enrollment open • Inherited Retinal Dystrophy • Retinal Disorders